Nilubol Naris, Weinstein Lee S, Simonds William F, Jensen Robert T, Marx Stephen J, Kebebew Electron
Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Ann Surg Oncol. 2016 Feb;23(2):416-23. doi: 10.1245/s10434-015-4865-9. Epub 2015 Nov 5.
Recently, some surgeons have suggested that minimally invasive parathyroidectomy guided by preoperative localizing studies of patients with multiple endocrine neoplasia type 1 (MEN1)-associated primary hyperparathyroidism (pHPT) provides an acceptable outcome while minimizing the risk of hypoparathyroidism. This study aimed to evaluate the outcome for MEN1 patients who underwent limited parathyroidectomy compared with subtotal parathyroidectomy.
The authors performed a retrospective analysis of 99 patients with MEN1-associated pHPT who underwent at least one parathyroid operation at their institution. Preoperative imaging studies, intraoperative findings, and clinical outcomes for patients were compared.
A total of 99 patients underwent 146 operations. Persistent pHPT was significantly higher in patients whose initial operations involved removal of 1 or 2 glands (69 %) or 2.5 to 3 glands (20 %) compared with those who had 3.5 or more glands removed (6 %) (P < 0.01). Persistent pHPT occurred in 5 % of all operations that cumulatively removed 3.5 or more parathyroid glands compared with 40 % of operations that removed 3 or fewer glands (P < 0.01). The single largest parathyroid gland was correctly identified preoperatively in 69 % (22/32) of the patients. However, preoperative localizing studies missed enlarged contralateral parathyroid glands in 86 % (19/22) of these patients. Preoperative localizing studies missed the largest contralateral parathyroid gland in 16 % (5/32) of the patients.
Limited parathyroidectomy in MEN1 is associated with a high failure rate and should not be performed. Preoperative identification of a single enlarged parathyroid gland in MEN1 is not reliable enough to justify unilateral neck exploration because additional enlarged contralateral parathyroid glands are frequently missed.
最近,一些外科医生提出,对于1型多发性内分泌腺瘤病(MEN1)相关原发性甲状旁腺功能亢进症(pHPT)患者,在术前定位研究引导下进行微创甲状旁腺切除术可获得可接受的结果,同时将甲状旁腺功能减退的风险降至最低。本研究旨在评估接受局限性甲状旁腺切除术的MEN1患者与次全甲状旁腺切除术患者的手术结果。
作者对99例在其机构接受至少一次甲状旁腺手术的MEN1相关pHPT患者进行了回顾性分析。比较了患者的术前影像学检查、术中发现和临床结果。
共有99例患者接受了146次手术。与切除3.5个或更多腺体的患者(6%)相比,初次手术切除1个或2个腺体(69%)或2.5至3个腺体(20%)的患者持续性pHPT发生率显著更高(P<0.01)。累计切除3.5个或更多甲状旁腺腺体的所有手术中,持续性pHPT发生率为5%,而切除3个或更少腺体的手术中这一比例为40%(P<0.01)。69%(22/32)的患者术前正确识别出最大的甲状旁腺腺体。然而,术前定位研究在这些患者中有86%(19/22)漏诊了对侧肿大的甲状旁腺腺体。16%(5/32)的患者术前定位研究漏诊了对侧最大的甲状旁腺腺体。
MEN1患者的局限性甲状旁腺切除术失败率高,不应进行。术前识别MEN1患者单个肿大的甲状旁腺腺体不够可靠,不足以证明单侧颈部探查的合理性,因为经常会漏诊额外的对侧肿大甲状旁腺腺体。